Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Abstract

Thrombocytosis is common in infancy and childhood. Essential thrombocythemia (ET), a myeloproliferative disorder, is a much less common cause of thrombocytosis in childhood. We report two cases of essential thrombocythemia in 5- and 10-year-old children, who presented with platelet counts of more than 1,000,000/mm(3). Treatment is not recommended for ET in an asymptomatic patient in the absence of bleeding or thrombosis and a platelet count <1,500,000/mm(3). Our first case had platelets >1,500,000/mm(3), and a second child was symptomatic with recurrent headache. Both responded well to therapy with hydroxyurea (dose 15-30 mg/kg/day) and tolerated it well.

• Authors: Vikas Dua, Satya Prakash Yadav, Vijay Kumar, Renu Saxena, Anupam Sachdeva
• Journal: International journal of hematology (Int J Hematol) Vol. 96 Issue 6 Pg. 810-3 (Dec 2012) ISSN: 1865-3774 [Electronic] Japan
• PMID: 23054653 (Publication Type: Case Reports, Journal Article)

Chemical References

• Janus Kinase 2
• Aspirin
• Hydroxyurea

Topics

• Aspirin (therapeutic use)
• Asymptomatic Diseases
• Bone Marrow (pathology)
• Child
• Child, Preschool
• Female
• Headache (etiology)
• Humans
• Hydroxyurea (therapeutic use)
• Janus Kinase 2 (genetics)
• Male
• Mutation, Missense
• Platelet Count
• Point Mutation
• Remission Induction
• Thrombocythemia, Essential (blood, diagnosis, drug therapy)